SkyePharma PLC Company Profile (LON:SKP)

About SkyePharma PLC (SKP)

SkyePharma PLC logoSkyepharma Ltd, formerly Skyepharma PLC, is a drug delivery company engaged in the development of oral and inhalation products. The Company operates as an independent developer of complex pharmaceutical products for global markets. Its principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies. It operates through the segment of development and supply of pharmaceutical products. It is also involved in the supply of products to its marketing partners, as in the case for flutiform and over seven oral products manufactured in its Lyon Facility. It operates primarily for respiratory applications. Its inhalation products include Relvar Ellipta/Breo Ellipta, Anoro Ellipta and Incruse Ellipta. Its oral products include RAYOS/LODOTRA, Requip Once-a-day, Xatral/Uroxatral, Madopar DR/Prolopa, Sular, ZYFLO CR, Paxil CR, Diclofenacratiopharm Uno, Triglide and Coruno.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SKP
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $466
  • 200 Day Moving Average: $408
  • 52-Week Range: GBX 249.25 - GBX 486.25
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A

Analyst Ratings

Consensus Ratings for SkyePharma PLC (LON:SKP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SkyePharma PLC (LON:SKP)
DateFirmActionRatingPrice TargetDetails
2/17/2016Stifel NicolausReiterated RatingBuyGBX 460View Rating Details
1/28/2016N+1 SingerReiterated RatingCorporateView Rating Details
1/22/2016FinnCapReiterated RatingBuyView Rating Details
12/23/2015RX SecuritiesReiterated RatingBuyView Rating Details
(Data available from 3/25/2015 forward)


Earnings History for SkyePharma PLC (LON:SKP)
No earnings announcements for this company have been tracked by


Earnings Estimates for SkyePharma PLC (LON:SKP)
Current Year EPS Consensus Estimate: $19.75 EPS


Dividend History for SkyePharma PLC (LON:SKP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for SkyePharma PLC (LON:SKP)
Insider Trades by Quarter for SkyePharma PLC (LON:SKP)
Insider Trades by Quarter for SkyePharma PLC (LON:SKP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/29/2016Derodra,AndrewInsiderBuy32GBX 473£151.36
3/31/2016Derodra,AndrewInsiderBuy33GBX 449£148.17
1/2/2016Grant,PeterInsiderBuy46GBX 327£150.42
11/30/2015Derodra,AndrewInsiderBuy46GBX 327£150.42
11/4/2015Grant,PeterInsiderBuy47GBX 322£151.34
10/30/2015Derodra,AndrewInsiderBuy47GBX 322£151.34
10/5/2015Grant,PeterInsiderBuy42GBX 354£148.68
9/4/2015Derodra,AndrewInsiderBuy48GBX 312£149.76
8/4/2015Grant,PeterInsiderBuy54GBX 279£150.66
7/3/2015Derodra,AndrewInsiderBuy55GBX 273£150.15
(Data available from 1/1/2013 forward)


Headline Trends for SkyePharma PLC (LON:SKP)
Latest Headlines for SkyePharma PLC (LON:SKP)


Frequently Asked Questions for SkyePharma PLC (LON:SKP)

What is SkyePharma PLC's stock symbol?

SkyePharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "SKP."

When will SkyePharma PLC make its next earnings announcement?

SkyePharma PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 16th 2016.

How do I buy SkyePharma PLC stock?

Shares of SkyePharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of SkyePharma PLC stock cost?

One share of SkyePharma PLC stock can currently be purchased for approximately GBX 444.

This page was last updated on 3/25/2017 by Staff